{"id":"NCT04058067","sponsor":"Novartis Pharmaceuticals","briefTitle":"To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema","officialTitle":"A One-Year, Randomized, Double-Masked, Multicenter, Phase III, Two-Arm Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Chinese Patients With Visual Impairment Due to Diabetic Macular Edema","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-08-23","primaryCompletion":"2023-01-31","completion":"2023-01-31","firstPosted":"2019-08-15","resultsPosted":"2024-09-19","lastUpdate":"2024-10-09"},"enrollment":266,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Macular Edema"],"interventions":[{"type":"DRUG","name":"Brolucizumab","otherNames":["RTH258"]},{"type":"DRUG","name":"Aflibercept","otherNames":["Eylea"]}],"arms":[{"label":"Brolucizumab 6 mg","type":"EXPERIMENTAL"},{"label":"Aflibercept 2 mg","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of Chinese patients with visual impairment due to Diabetic Macular Edema.","primaryOutcome":{"measure":"Change From Baseline at Week 52 in Best-corrected Visual Acuity (BCVA) for the Study Eye.","timeFrame":"Baseline to Week 52","effectByArm":[{"arm":"Brolucizumab 6 mg","deltaMin":10.6,"sd":0.85},{"arm":"Aflibercept 2 mg","deltaMin":11.9,"sd":0.85}],"pValues":[{"comp":"OG000 vs OG001","p":"0.013"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":8},"locations":{"siteCount":24,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=1867"]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":132},"commonTop":["Hyperlipidaemia","Hypertension","Visual acuity reduced - Fellow eye","Visual acuity reduced - Study eye","Upper respiratory tract infection"]}}